TFRC and cancer: Previous research has proposed that ruthenium complexes, including KP1019, preferentially accumulate in cancer cells compared to non-cancer cells through transferrin receptor-mediated endocytosis, attributed to the heightened expression of these receptors on the surface of cancer cells [4,5,6,46].